Signal Averaged ECG Parameters following Administration of Sotalol in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy
Message:
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Background

Sotalol is the most effective anti-arrhythmic drug in patients with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).

Objective

This retrospective study aimed to evaluate the effect of sotalol on Signal Averaged ECG (SAECG) parameters in patients with ARVC.

Methods

This retrospective study was performed on 11 ARVC patients who were recruited from the cardiology clinic. SAECG was performed in all patients at baseline and six weeks after treatment with sotalol. To assess the effects of sotalol on SAECG, the three following parameters were taken into account: 1) filtered QRS duration, 2) duration of terminal QRS < 40 µv, and 3) Root Mean Square (RMS) voltage of terminal 40 ms. Patients with coronary artery disease, dilative or hypertrophic cardiomyopathy, congenital heart disease, and significant valvular heart disease were excluded from the study.

Results

In total, 11 patients with confirmed ARVC were included. The mean age of the participants was 28 ± 11 years and all patients were male. History of syncope was reported in four patients, ventricular tachycardia in three patients, positive family history of cardiac disorders in two patients, and Epsilone wave in four patients. Besides, Implantable Cardioverter Defibrillators (ICDs) were implanted in five patients. No significant change was detected in the filtered QRS duration following the use of sotalol (P = 0.542). However, a significant reduction was observed in the Low Amplitude Signal (LAS) duration below 40 µv (P = 0.002). Additionally, a significant increase was found in the RMS voltage in the last 40 ms of the QRS (P = 0.043).

Conclusion

Sotalol decreased the duration of terminal QRS < 40 µv. Because of this valuable effect, sotalol should be considered as the first-line therapy for treating ARVC patients.

Language:
English
Published:
International Cardiovascular Research Journal, Volume:14 Issue: 2, Jun 2020
Pages:
39 to 41
magiran.com/p2140900  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 990,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
دسترسی سراسری کاربران دانشگاه پیام نور!
اعضای هیئت علمی و دانشجویان دانشگاه پیام نور در سراسر کشور، در صورت ثبت نام با ایمیل دانشگاهی، تا پایان فروردین ماه 1403 به مقالات سایت دسترسی خواهند داشت!
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 50 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!